Results 51 to 60 of about 1,093 (174)

Multi‐Targeting Ligands as Prospective Therapeutics for Alzheimer's Disease, a Prevalent Neurodegenerative Disorder: Mechanistic Insights, Emerging Targets and Drug Discovery Campaigns

Medicinal Research Reviews, Volume 46, Issue 4, Page 1173-1229, July 2026.
ABSTRACT Alzheimer's disease (AD) is a debilitating neurodegenerative condition characterized by progressive cognitive impairment, memory deterioration, and neuronal dysfunction. Its complex pathophysiology involves multiple interlinked processes, including amyloid‐β (Aβ) aggregation, tau hyperphosphorylation, oxidative stress, neuroinflammation ...
Amandeep Thakur, Mandeep Rana, Sakshi Vanjani, Kei‐Chi Liou, Rajeev Taliyan, Kunal Nepali, Chih‐Hao Yang   +6 more
wiley   +1 more source

Consistency and clarity of pharmacogenomic guidance in UK medicine patient information leaflets: A cross‐sectional analysis

British Journal of Clinical Pharmacology, Volume 92, Issue 6, Page 1934-1939, June 2026.
Pharmacogenomic (PGx) information has the potential to support the safe and effective use of medicines, yet there is uncertainty about how this information can be best communicated to patients. Summaries of product characteristics (SmPCs) and patient information leaflets (PILs) for all UK‐approved medicines with strong evidence supporting a PGx ...
Parth Narlawar, Chloe Ratcliffe, Videha Sharma, William G. Newman, Munir Pirmohamed, John McDermott   +5 more
wiley   +1 more source

Anti‐Obesity Pharmacotherapy and Emerging Multimodal Interventions for Obstructive Sleep Apnea

Chronic Diseases and Translational Medicine, Volume 12, Issue 2, Page 100-112, June 2026.
Cellular and molecular mechanisms of obesity‐related obstructive sleep apnea (OSA). ADMA: asymmetric dimethyrarginine, NLRP3: nucleotide‐binding domain, leucine‐rich repeat family, Pyrin domain containing 3, TLR: toll‐like receptors, IL‐1β: interleukin‐1β, IL‐6: interleukin‐6; LPS: lipopolysacharide, ROS: reactive oxygen species, TNF‐α.
Anish Preshy, Cornelius J. Fernandez, Mohammad Hamid Nedai, Joseph M. Pappachan   +3 more
wiley   +1 more source

Attention‐deficit hyperactivity disorder in children and young persons during the COVID‐19 pandemic. A temporal trends analysis of electronic heath records in Greater Manchester, England

JCPP Advances, Volume 6, Issue 2, June 2026.
Abstract Background The incidence of attention‐deficit hyperactivity disorder (ADHD) in children and young people has increased in recent years. Disease frequency varies according to sociodemographic characteristics. There are seasonal patterns in ADHD diagnosis and prescribing with rates falling during school holidays.
Louise Hussey, Evangelos Kontopantelis, Pearl L. H. Mok, Darren M. Ashcroft, Shruti Garg, Carolyn A. Chew‐Graham, Karina Lovell, Roger T. Webb   +7 more
wiley   +1 more source

Narcolepsy in the light of modern diagnostic, clinical and therapeutic concepts

Journal of Education, Health and Sport, 2018
Narcolepsy is a chronic neurological disease classified as hypersomnia of central origin. Core symptoms of the disease (hypersomnia and cataplexy) are particularly burdensome for patients. The etiology of the disease is not fully understood.
Adrian Kowalski, Iwona Kowalska, Magdalena Kowalska, Wiktor Dróżdż, Alicja Nowaczyk   +4 more
doaj   +3 more sources

Selective H3 Antagonist (ABT-239) Differentially Modifies Cognitive Function Under the Impact of Restraint Stress

Frontiers in Systems Neuroscience, 2021
Background: A considerable number of competitive antagonists/inverse agonists of histamine H3 receptor (H3R) have progressed to clinical assessment, with pitolisant approved for the treatment of narcolepsy.
Emil Trofimiuk, Przemysław Wielgat, Halina Car   +2 more
doaj   +1 more source

Pitolisant: What is it and what is it used for? Authors: Michael K Haldorson

, 2023
IntroductionFatigue and excessive daytime sleepiness are common concerns. But many symptomatictreatments have potential for abuse or dependence, limiting use.Pitolisant, an antagonist/inverse agonist of histamine H3 receptors, received European ...
Haldorson, Michael
core  

Multiple Targeting Approaches on Histamine H3 Receptor Antagonists

Frontiers in Neuroscience, 2016
With the very recent market approval of pitolisant (Wakix®), the interest in clinical applications of novel multifunctional histamine H3 receptor antagonists has clearly increased. Since histamine H3 receptor antagonists in clinical development have been
Mohammad eKhanfar, Anna eAffini, Kiril eLutsenko, Katarina eNikolic, Stefania eButini, Holger eStark   +5 more
doaj   +1 more source

Sleep Reactivity Amplifies the Impact of Pre‐Sleep Cognitive Arousal on Sleep Disturbances

Journal of Sleep Research, Volume 35, Issue 3, June 2026.
This study investigates how sleep reactivity moderates the ‘stress‐pre‐sleep arousal‐sleep’ pathway in university students. At the within‐individual level, both high and low sleep‐reactive groups showed increased pre‐sleep cognitive arousal and sleep disruptions in response to elevated daily stress.
Noof Abdullah Saad Shaif, Julian Lim, Anthony N. Reffi, Michael W. L. Chee, Stijn A. A. Massar, Ju Lynn Ong   +5 more
wiley   +1 more source

Pharmacological and Mechanistic Interventions for Cognitive Impairment Associated With Schizophrenia: A Review of Registered Clinical Trials

Acta Psychiatrica Scandinavica, Volume 153, Issue 5, Page 402-431, May 2026.
ABSTRACT Background Schizophrenia is characterized by positive, negative, and cognitive symptoms. Current pharmacological treatments often fail to address cognitive deficits. In this review of clinical trials, we aim to identify studies that explore neurobiological (non‐psychological) strategies to address Cognitive Impairment Associated with ...
Bahareh Peyrovian, Lena Palaniyappan, Theodore T. Kolivakis, Howard C. Margolese   +3 more
wiley   +1 more source